Is the future of medicine innovative? Why did the General Assembly experts say that?

With the expansion of the global pharmaceutical market, the number and scale of Chinese pharmaceutical enterprises have increased Innovative drugs have always been the Pearl of the pharmaceutical industry crown Increase the proportion of new innovative drugs in the national medical insurance catalogue; reduce the average time from listing to inclusion of mainstream innovative drugs in the medical insurance to within one year; increase the proportion of domestic innovative drugs in the medical insurance to 100% The continuous optimization of the domestic policy environment, the increasing capital injected into the pharmaceutical industry, and the return of a large number of high-tech talents will vigorously promote the development of the domestic innovative drug market and accelerate the innovation and R & D of domestic pharmaceutical enterprises in line with international standards In such an environment, how to deal with the opportunities and challenges brought by the new drug policy, how to realize the upgrading of innovative drug industry under the new drug policy, how to correctly evaluate the hot spots of new drug research and development oriented by clinical value, and how to draw lessons from the transfer and introduction of overseas rights and interests of innovative drugs will become the focus of attention in the field of domestic innovative drugs In December, Beijing xinkaiyuan Pharmaceutical Technology Co., Ltd., Chongqing Yaoyou Pharmaceutical Co., Ltd and yaozhi.com will jointly hold the "innovative drug development strategy seminar" in Chongqing International Expo Center This forum belongs to the sub forum of "2019 drug fair" We sincerely invite domestic experts in the field of innovative drugs, pharmaceutical enterprises, industry media, etc to come together, uphold the concept of cooperation and win-win, and explore together Discuss hot issues such as new drug development trends and key technologies, and jointly promote the healthy development of China's pharmaceutical industry At that time, we look forward to your visit! Best regards! Theme: Huizhi innovation departure future time: December 4, 2019 (Wednesday) all day Venue: Chongqing International Expo Center organizer: Beijing xinkaiyuan Pharmaceutical Technology Co., Ltd and Chongqing Yaoyou Pharmaceutical Co., Ltd jointly sponsored: Yaozhi network scale: 200 person conference highlights 1 Pharmaceutical grand gathering, sharing the grand event Several industry leaders and domestic innovative medicine elites gathered together to discuss cooperation and development plans, in-depth exchanges, and integrate industrial resources 2 Innovation driven, leading the navigation to bring together the elites of pharmaceutical innovative drugs, focusing on the research and development trend of innovative drugs at home and abroad, focusing on the analysis of relevant policies and market environment, guiding domestic innovative drug enterprises to avoid research and development risks, controlling future research and development points, and reducing research and development costs 3 Pharmaceutical oriented, market value top pharmaceutical enterprises gather in China, business elites conspire for new market environment defects, throw out new ideas, and lead the new trend of pharmaceutical market 1 Zhu Xizhen, deputy general manager of Beijing xinkaiyuan Pharmaceutical Technology Co., Ltd (innovative medicine), Research Triangle Institute (United States), postdoctoral doctor of pharmaceutical chemistry, has worked for 20 years and obtained 3 invention patents He used to be a senior scientist in drug R & D center of Johnson & Johnson company, chairman of Xiamen Xinlikang Biotechnology Co., Ltd., vice president of Fujian Jinle Pharmaceutical Co., Ltd and Fujian Haixi new drug creation Co., Ltd 2 Li Mei graduated from school of pharmacy, Beijing Medical University in 1982 with a bachelor's degree in pharmaceutical chemistry 1982-1993: Institute of pharmaceutical biotechnology, Chinese Academy of Medical Sciences, successively served as research intern, assistant researcher and associate researcher, and was appointed as the director of development division of scientific research division in 1992; 1994-2000: head of chemical medicine group of drug review center; 2000-2002: head of chemical medicine and biological products room and head of chemical medicine group of drug review center 2002-2012: Assistant to the director of the Institute of pharmaceutical biotechnology, Chinese Academy of Medical Sciences and director of the preparation room; April 2014-july 2019: as an expert, he was reemployed back to the drug review center, and served as the person in charge of the generic drug filing review team and the chemical generic drug consistency evaluation product filing review team 3 Guo Jianjun, general manager and head of organization of Hunan Hengxing Pharmaceutical Technology Co., Ltd., has nearly 15 years of research and management experience in the field of biomedicine, and is good at pharmacokinetic (DMPK), biological analysis, separation science, mass spectrometry, qualitative and quantitative analysis, proteomics and other aspects of research He has presided over and participated in the overall DMPK research projects of more than 50 new drugs, and led more than 40 biological sample analysis projects applying for be research At present, nearly 20 SCI papers and reviews have been published, and 16 national invention and utility model patents have been obtained 4 Liang Maozhi, deputy director of national drug clinical trial organization and director of phase I clinical trial Laboratory of West China Hospital, and guest researcher of national safety evaluation center of traditional Chinese medicine of West China Hospital of Sichuan University Member of the expert database of new drug review of the State Food and drug administration, member of the new drug review committee of the State Food and Drug Administration of Sichuan Province, and member of the expert database of drug safety evaluation of Sichuan Province In recent years, as the person in charge of the project, he has undertaken and completed more than 50 phase I clinical research projects of 1-5 new drugs of the State Food and drug administration, and one project of the Provincial Department of science and technology As the main researcher, he participated in one major special project of the Ministry of science and technology of the people's Republic of China, and completed five projects funded by the National Natural Science Foundation and the Provincial Department of health He is the editor in chief of 6 monographs and textbooks published by the people's Health Press, such as "rational use of drugs for respiratory diseases" He has published more than 100 academic papers in core journals and statistical source journals 5 Meng Bayi, master of pharmaceutical chemistry, master of computer science, New York City University, former intellectual property director, consultant and deputy general manager of Chongqing Huabang Pharmaceutical Co., Ltd He was a patent agent of China Patent Agency (Hong Kong) Co., Ltd 6 Yu Yongping, Zhuhai tus Boda Investment Management Co., Ltd 7, Chen Xiaoyong, chairman of Chongqing Dongde Pharmaceutical Technology Co., Ltd., well-known expert, entrepreneur, senior engineer in Chongqing pharmaceutical industry, visiting professor and graduate supervisor of Chongqing University In 1990, he graduated from Tongji Medical College of Huazhong University of science and technology with a master's degree in pharmaceutical chemistry He once held important positions in many famous pharmaceutical enterprises He successively served as the deputy chief engineer of Chongqing pharmaceutical industry research institute, the founder of Chongqing renben Pharmaceutical Research Institute, and the deputy general manager of Chongqing Fu'an Pharmaceutical Group 8 Li Tianquan, senior engineer, co-founder and vice president of yaozhi.com, has been engaged in the research and development of the pharmaceutical industry for a long time He has undertaken a number of national and provincial research and development projects, obtained 5 national invention patents, served as the director of new drug research and development for many years, and successfully developed dozens of new products In recent years, he has been absorbed in the construction and utilization of medical database, and jointly established a professional China's leading medical big data service platform, yaozhi.com, which specializes in the retrieval and utilization of medical information He is good at interpreting industrial policies and hot medical information through the mining of professional data, deeply analyzing the development status and trend of the pharmaceutical industry, and helping enterprises make decisions This meeting is free of charge The organizing committee will provide you with the relevant information of the meeting, such as the journal, information bag, etc Registration link: https://c.eqxu.com/s/czenf49n meeting contact